Home  /  Resource Library  /  Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

ASH 2019: Results of a phase I/II study investigating the combination of Brentuximab Vedotin and Nivolumab for treatment of relapsed Hodgkin.